Type 1 diabetes cure research: the trials worth following in 2026

I want to be careful with the word “cure,” because hope is precious and it has been sold cheaply before. So let me be clear about what this article is. It is not a promise. Most experimental treatments never reach the clinic, and timelines slip. But the research has reached a point that genuinely deserves your attention — and, if you choose, your participation.

To make sense of it, it helps to know that type 1 diabetes is really two problems at once. First, the immune system mistakenly destroys the beta cells in the pancreas that make insulin. Second, once those cells are gone, the body can no longer control blood sugar on its own. A true cure has to answer both — and the trials below split neatly into the strategies that tackle each side.

There are three broad approaches. Replace the lost cells (with transplanted or lab-grown insulin-making cells). Calm or retrain the immune attack (so it stops destroying beta cells). Or protect the cells someone still has, especially right after diagnosis. Some of the most exciting work combines them.

The trials, side by side

Below is a filterable tracker of the most notable programmes. Tap any card to open the full detail — what it is, who can take part (including age), results so far, the honest pros and cons, and a link to the official study on ClinicalTrials.gov. Filter by country, whether it's recruiting, whether it's free to join, interventional or observational, approach or phase — and open the glossary if a term is new. It also includes free screening studies (like TrialNet and the UK's ELSA) that are often the first step to taking part. Every fact here was checked against the trial registry and sponsor reports in July 2026.

Replacing the cells: the closest thing to a functional cure

The furthest-advanced programme is Vertex's zimislecel (VX-880), now in a Phase 3 study called FORWARD. It infuses lab-grown, insulin-making islet cells into the liver's blood supply. The early results are the kind we have waited decades for: of the first 12 patients followed for a year, the company reports that 10 came off insulin completely, and all reached healthy blood-sugar targets and stopped having severe hypos. It builds on the same principle as the donor islet cell transplants that have quietly restored insulin independence in a small number of people.

There is one large catch, and it applies to almost every cell-replacement approach: recipients must take immune-suppressing drugs for life so the body doesn't reject or re-attack the new cells. Those drugs carry real risks, which is why, for now, these trials are limited to people whose diabetes is hardest to manage — usually severe, unpredictable hypoglycaemia.

That is exactly why two other efforts matter so much. A University of Chicago study pairs an islet transplant with a gentler antibody called tegoprubart instead of the usual harsh anti-rejection drugs — and reports that all 12 recipients so far are insulin-independent. And in Sweden, Sana Biotechnology's team gene-edited donor islet cells to “hide” from the immune system and placed them in one patient with no anti-rejection drugs at all; the cells survived and made insulin for over a year. That single patient, published in a top medical journal, is a proof of principle that could eventually remove the immunosuppression problem entirely.

One more milestone is worth knowing: in China, doctors reprogrammed a woman's own fat cells into stem cells, turned them into islets, and transplanted them — no donor needed. She became insulin-independent and stayed that way at one year. It was a single case (and she was already on immune-suppressing drugs from an earlier transplant), but using a person's own cells is a genuine step toward sidestepping both the donor shortage and rejection.

Calming the immune attack

The other half of the field tries to stop the immune system attacking beta cells in the first place. This is where the only approved disease-modifying treatment lives: teplizumab (TZIELD). In people at high risk — found through antibody screening, often relatives of someone with type 1 — a two-week course delays the onset of full diabetes by about two years on average. As of April 2026 it is approved in the US from age 1. It does not cure or prevent, but it is the first drug ever shown to change the course of type 1, and it is available now.

Several others are following. Sanofi's frexalimab and, notably, an existing arthritis tablet called baricitinib both aim to protect the insulin a newly-diagnosed person still has. Baricitinib is especially interesting because it is a cheap, daily pill rather than an infusion, and its Phase 2 results were strong enough to publish in the New England Journal of Medicine; a Phase 3 is now recruiting. Sweden's Diamyd takes a precision route — a lymph-node “vaccine” that only works in people with a particular gene type. And in Poland, PolTREG is testing whether a child's own calming immune cells can prevent type 1 before it ever starts.

The honest part: what has recently failed

Trust matters more than hype, so here is the other side. In 2025, Vertex's VX-264 — an encapsulated cell therapy designed to avoid immunosuppression — was discontinued after it didn't produce enough insulin. The immunotherapy IMCY-0098 was stopped for lack of effect. And the definitive adult trial of verapamil, a blood-pressure drug once hoped to preserve beta cells, came back negative (an earlier study in children had shown a modest signal, so the idea isn't fully dead — but the big adult trial did not work).

Two long-running approaches remain genuinely contested. The repeat BCG vaccine work and “Stem Cell Educator” therapy both have loyal followings and years of small studies, but their claims have not been independently reproduced, and mainstream diabetes researchers urge real caution. I have included both in the tracker with clear warnings, because you deserve to see them and to see why experts are sceptical — not to have them quietly left out.

How to actually follow — or join — a trial

If a programme interests you, here is how to go further. Every entry in the tracker links to its official page on ClinicalTrials.gov ↗, the public registry — search the NCT number to see live recruiting status, the exact eligibility criteria, and the contact details for each site. “Recruiting” means they are actively enrolling; “active, not recruiting” means the group is full.

A few practical notes. Many prevention and early-intervention trials (including the path to teplizumab) start with autoantibody screening, which relatives of people with type 1 can often get free through research programmes like TrialNet and, in Europe, ELSA. Trials have strict criteria — age, how long you've had diabetes, how much of your own insulin is left — so don't be discouraged if one doesn't fit; another may. And never stop or change your current treatment for a trial without your diabetes team; bring the study's page to your appointment and decide together.

For the bigger picture on where diabetes science is heading — including how the field is starting to treat these as several different diseases rather than one — you might also find my note on what new research says about type 2 diabetes useful.

What the research says

I will keep this tracker updated as trials read out and new ones open. After more than two decades of “five years away,” I am not going to promise you a date. But for the first time, I can point to real people, in real trials, living without insulin — and tell you exactly where to look.